The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective

Lloyd, Adam; Boomershine, Chad S.; Choy, Ernest; Chandran, Arthi; Zlateva, Gergana

doi:10.3111/13696998.2012.660254

Cited by 19 publications

(24 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 255 abstracts, based on the inclusion criteria, 56 were selected for further review in full text. In the past 11 years, 55 publications examined economic outcomes associated with pregabalin in FM or neuropathic pain . These 55 publications presented results from 53 studies.…”

Section: Resultsmentioning

confidence: 99%

“…Twenty‐one economic evaluations were found for pregabalin in FM and neuropathic pain . The cost‐effectiveness of pregabalin was assessed with cost‐utility, cost‐effectiveness, and cost‐consequence analyses, most often in the US and Western European countries, but also in Canada, Brazil, Colombia, and Mexico (Table S2).…”

Section: Resultsmentioning

confidence: 99%

“…Seven US models assessed the cost‐effectiveness of pregabalin for FM and neuropathic pain associated with PHN and painful pDPN . These economic analyses suggested that pregabalin might not be cost‐effective versus its comparators for PHN or painful pDPN.…”

Section: Resultsmentioning

confidence: 99%

“…A cost‐effectiveness model presented by Lloyd et al. from the societal perspective showed that pregabalin 150 mg or 225 mg was as least as effective and cost‐saving, that is, dominant vs. most other treatments (placebo, duloxetine, gabapentin, tramadol, milnacipran, and amitriptyline) for severe FM over a 1‐year time horizon …”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

A Systematic Review of Pharmacoeconomic Studies for Pregabalin

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

A Systematic Review of Pharmacoeconomic Studies for Pregabalin

et al. 2014

View full text Add to dashboard Cite

show abstract

“…They concluded that pregabalin is a cost-effective treatment. In another study in the US [32], a cost-effectiveness analysis was conducted to compare different fibromyalgia management strategies by a decision-analytic model and indirect effectiveness comparison. The results indicated that pregabalin is cost-saving and more effective than placebo, duloxetine, tramadol, milnacipran, and gabapentin.…”

Section: Discussionmentioning

confidence: 99%

Systematic review/Meta-analysis A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience

Keshavarz¹,

Hashemi-Meshkini²,

Gharibnaseri³

et al. 2013

aoms

View full text Add to dashboard Cite

IntroductionFibromyalgia is a neuropathic syndrome which is more common in adult females. Pregabalin is the first medicine which was approved by the United States Food and Drug Administration for treatment of fibromyalgia. In this study we aimed to evaluate the cost-efficacy of pregabalin in the treatment of fibromyalgia in Iran.Material and methodsTo evaluate the efficacy of pregabalin, a systematic review was carried out by conducting a wide literature search for the main outcomes of interest that were pain score reduction from the baseline and the percentage of patients with more than 50% pain reduction. To evaluate costs of treatment, only the direct medical costs were considered. The calculated incremental cost-effectiveness ratio (ICER) were compared with one and three times the gross domestic product (GDP) per capita as the threshold to evaluate the economic condition of treatment to be “highly cost-effective”, “cost-effective” or “not cost-effective”.ResultsOut of 4012 searched reports, only four reports were included in the study, all of which were randomized controlled trials with placebo controls. The calculated ICERs for pregabalin 450 mg/day and 600 mg/day with both available forms of brand and generic medicines in the country were in the range of 44–1170 US dollars (USD) and 48–814 USD, which in all cases could be considered as highly cost-effective. Pregabalin 150 mg/day based on available evidence does not have significant efficacy in comparison to placebo. But for pregabalin 300 mg/day, no decision can be made based on current data.ConclusionsOur analysis indicated that generic pregabalin in the treatment doses of 450 mg/day and 600 mg/day is highly cost-effective.

show abstract

Implications and mechanism of action of gabapentin in neuropathic pain

et al. 2013

View full text Add to dashboard Cite

Gabapentin is an anti-epileptic agent but now it is also recommended as first line agent in neuropathic pain, particularly in diabetic neuropathy and post herpetic neuralgia. α2δ-1, an auxillary subunit of voltage gated calcium channels, has been documented as its main target and its specific binding to this subunit is described to produce different actions responsible for pain attenuation. The binding to α2δ-1 subunits inhibits nerve injury-induced trafficking of α1 pore forming units of calcium channels (particularly N-type) from cytoplasm to plasma membrane (membrane trafficking) of pre-synaptic terminals of dorsal root ganglion (DRG) neurons and dorsal horn neurons. Furthermore, the axoplasmic transport of α2δ-1 subunits from DRG to dorsal horns neurons in the form of anterograde trafficking is also inhibited in response to gabapentin administration. Gabapentin has also been shown to induce modulate other targets including transient receptor potential channels, NMDA receptors, protein kinase C and inflammatory cytokines. It may also act on supra-spinal region to stimulate noradrenaline mediated descending inhibition, which contributes to its anti-hypersensitivity action in neuropathic pain.

show abstract

The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective

Abstract: This model found pregabalin to be cost-effective in treating patients with severe fibromyalgia.

Cited by 19 publications

References 45 publications

A Systematic Review of Pharmacoeconomic Studies for Pregabalin

A Systematic Review of Pharmacoeconomic Studies for Pregabalin

Systematic review/Meta-analysis A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience

Implications and mechanism of action of gabapentin in neuropathic pain

Contact Info

Product

Resources

About